Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- NYU Langone Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All subjects will have participated in prior CBH studies and have agreed to an FDG, PIB and MRI scans.
Exclusion Criteria:
- Diagnosis of sleep apnea and under treatment with a continuous positive airway pressure (CPAP) machine.
- Active depressive episode during the evaluation with a Geriatric Depression Scale score >7 and/or a Clinical Global Impression scale for depression score >4.
- Moderate Cognitive decline (GDS >3).
- Severe primary or secondary insomnia except insomnia due to SDB.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Mild Cognitive Impairment (MCI)
Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
|
measures of global and hippocampal atrophy)
brain blood flow
reduced vaso reactivity to carbon dioxide
|
|
Normal Cognition (NL)
Clinical Dementia Rating [CDR] of 0 or Global Deterioration Scale [GDS] of 1-2
|
measures of global and hippocampal atrophy)
brain blood flow
reduced vaso reactivity to carbon dioxide
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decreased cerebral blood flow (CBF)
Time Frame: 1 Week
|
Measured by perfusion MRI
|
1 Week
|
|
Measure of vasoreactivity to CO2 (VRCO2)
Time Frame: 1 Week
|
subjects will breath through a respiratory tube and CO2 will be meaured
|
1 Week
|
|
Increase in cortical AB plaque burden
Time Frame: 1 Week
|
Measured by PIB PET
|
1 Week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ricardo Osorio, MD, NYU Langone Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Apnea
- Respiration Disorders
- Sleep Disorders, Intrinsic
- Dyssomnias
- Neurologic Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Sleep Apnea Syndromes
- Sleep Wake Disorders
- Alzheimer Disease
- Cognitive Dysfunction
Other Study ID Numbers
Other Study ID Numbers
- 12-00041
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.